Havervall S

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster

Marking U, Bladh O, Aguilera K, ..., Sheward DJ, Thålin C

- - (-) - [2023-12-21; online 2023-12-21]

Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.

Havervall S, Marking U, Greilert-Norin N, ..., Åberg M, Thålin C

Clin Transl Immunology 11 (4) e1388 [2022-04-18; online 2022-04-18]

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.

Marking U, Havervall S, Greilert-Norin N, ..., Åberg M, Thålin C

Vaccines (Basel) 10 (3) - [2022-02-24; online 2022-02-24]

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.

Havervall S, Ng H, Jernbom Falk A, ..., Hober S, Thålin C

J. Intern. Med. 291 (1) 72-80 [2022-01-00; online 2021-09-27]

Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay.

Hober S, Hellström C, Olofsson J, ..., Hedhammar M, Nilsson P

Clin Transl Immunology 10 (7) e1312 [2021-07-19; online 2021-07-19]

SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection

Havervall S, Falk AJ, Klingström J, ..., Nilsson P, Thålin C

- - (-) - [2021-01-04; online 2021-01-04]